Klaria Pharma Holding AB Holds Extraordinary General Meeting, Approves Rights Offering
Klaria Pharma Holding AB held an extraordinary general meeting where it was resolved to conduct a rights offering. The meeting also approved other proposals presented.
Klaria Pharma Holding AB (publ) convened an extraordinary general meeting today, passing resolutions crucial for the company's future operations. The primary decision involved a unanimous resolution to proceed with a rights offering, potentially comprising up to 61,494,038 units.
The right to subscribe for units with preferential rights will be granted to shareholders registered on the record date for the rights offering, set for October 12, 2026. This date determines eligibility for participation in the new issuance.
In addition to the rights offering, all other proposals presented to the meeting were approved. These proposals were made available on the company’s website and aligned with the notice of the meeting.
Klaria Pharma focuses on developing pharmaceutical solutions for pain and neurological conditions. The decision to pursue a rights offering is a key element of its financial strategy, aimed at funding ongoing research and development activities.